Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides.

Hulea L, Gravel SP, Morita M, Cargnello M, Uchenunu O, Im YK, Lehuédé C, Ma EH, Leibovitch M, McLaughlan S, Blouin MJ, Parisotto M, Papavasiliou V, Lavoie C, Larsson O, Ohh M, Ferreira T, Greenwood C, Bridon G, Avizonis D, Ferbeyre G, Siegel P, Jones RG, Muller W, Ursini-Siegel J, St-Pierre J, Pollak M, Topisirovic I.

Cell Metab. 2018 Sep 17. pii: S1550-4131(18)30566-7. doi: 10.1016/j.cmet.2018.09.001. [Epub ahead of print]

PMID:
30244971
2.

Interplay between ShcA Signaling and PGC-1α Triggers Targetable Metabolic Vulnerabilities in Breast Cancer.

Im YK, Najyb O, Gravel SP, McGuirk S, Ahn R, Avizonis DZ, Chénard V, Sabourin V, Hudson J, Pawson T, Topisirovic I, Pollak M, St-Pierre J, Ursini-Siegel J.

Cancer Res. 2018 Sep 1;78(17):4826-4838. doi: 10.1158/0008-5472.CAN-17-3696. Epub 2018 Jun 21.

PMID:
29930100
3.

Integration of Distinct ShcA Signaling Complexes Promotes Breast Tumor Growth and Tyrosine Kinase Inhibitor Resistance.

Ha JR, Ahn R, Smith HW, Sabourin V, Hébert S, Cepeda Cañedo E, Im YK, Kleinman CL, Muller WJ, Ursini-Siegel J.

Mol Cancer Res. 2018 May;16(5):894-908. doi: 10.1158/1541-7786.MCR-17-0623. Epub 2018 Feb 16.

PMID:
29453318
4.

Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity.

Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan HKM, Haakensen VD, Helland Å, Naume B, Caldas C, Børresen-Dale AL, Kristensen VN, Troyanskaya OG.

Oncotarget. 2017 Jul 7;8(34):57121-57133. doi: 10.18632/oncotarget.19078. eCollection 2017 Aug 22.

5.

The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression.

Ahn R, Sabourin V, Bolt AM, Hébert S, Totten S, De Jay N, Festa MC, Young YK, Im YK, Pawson T, Koromilas AE, Muller WJ, Mann KK, Kleinman CL, Ursini-Siegel J.

Nat Commun. 2017 Mar 9;8:14638. doi: 10.1038/ncomms14638.

6.

The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness.

Ha JR, Siegel PM, Ursini-Siegel J.

J Cell Biochem. 2016 Sep;117(9):1971-90. doi: 10.1002/jcb.25561. Epub 2016 Apr 14. Review.

PMID:
27392311
7.

STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis.

Jones LM, Broz ML, Ranger JJ, Ozcelik J, Ahn R, Zuo D, Ursini-Siegel J, Hallett MT, Krummel M, Muller WJ.

Cancer Res. 2016 Mar 15;76(6):1416-28. doi: 10.1158/0008-5472.CAN-15-2770. Epub 2015 Dec 30.

8.

The influence of the pre-metastatic niche on breast cancer metastasis.

Ursini-Siegel J, Siegel PM.

Cancer Lett. 2016 Sep 28;380(1):281-8. doi: 10.1016/j.canlet.2015.11.009. Epub 2015 Nov 11. Review.

PMID:
26577808
9.

Tungsten targets the tumor microenvironment to enhance breast cancer metastasis.

Bolt AM, Sabourin V, Molina MF, Police AM, Negro Silva LF, Plourde D, Lemaire M, Ursini-Siegel J, Mann KK.

Toxicol Sci. 2015 Jan;143(1):165-77. doi: 10.1093/toxsci/kfu219. Epub 2014 Oct 15.

10.

The prognostic ease and difficulty of invasive breast carcinoma.

Tofigh A, Suderman M, Paquet ER, Livingstone J, Bertos N, Saleh SM, Zhao H, Souleimanova M, Cory S, Lesurf R, Shahalizadeh S, Garcia Lopez N, Riazalhosseini Y, Omeroglu A, Ursini-Siegel J, Park M, Dumeaux V, Hallett M.

Cell Rep. 2014 Oct 9;9(1):129-142. doi: 10.1016/j.celrep.2014.08.073. Epub 2014 Oct 2.

11.

p66ShcA promotes breast cancer plasticity by inducing an epithelial-to-mesenchymal transition.

Hudson J, Ha JR, Sabourin V, Ahn R, La Selva R, Livingstone J, Podmore L, Knight J, Forrest L, Beauchemin N, Hallett M, Park M, Ursini-Siegel J.

Mol Cell Biol. 2014 Oct 1;34(19):3689-701. doi: 10.1128/MCB.00341-14. Epub 2014 Jul 28.

12.

Peripheral blood cells inform on the presence of breast cancer: a population-based case-control study.

Dumeaux V, Ursini-Siegel J, Flatberg A, Fjosne HE, Frantzen JO, Holmen MM, Rodegerdts E, Schlichting E, Lund E.

Int J Cancer. 2015 Feb 1;136(3):656-67. doi: 10.1002/ijc.29030. Epub 2014 Jun 25.

13.

The ShcA adaptor activates AKT signaling to potentiate breast tumor angiogenesis by stimulating VEGF mRNA translation in a 4E-BP-dependent manner.

Im YK, La Selva R, Gandin V, Ha JR, Sabourin V, Sonenberg N, Pawson T, Topisirovic I, Ursini-Siegel J.

Oncogene. 2015 Mar 26;34(13):1729-35. doi: 10.1038/onc.2014.110. Epub 2014 May 19.

PMID:
24837366
14.

The ShcA PTB domain functions as a biological sensor of phosphotyrosine signaling during breast cancer progression.

Ahn R, Sabourin V, Ha JR, Cory S, Maric G, Im YK, Hardy WR, Zhao H, Park M, Hallett M, Siegel PM, Pawson T, Ursini-Siegel J.

Cancer Res. 2013 Jul 15;73(14):4521-32. doi: 10.1158/0008-5472.CAN-12-4178. Epub 2013 May 21.

15.

It takes two to tango in the microenvironment!

Ursini-Siegel J, Park M.

Breast Cancer Res. 2013 Mar 12;15(2):102. doi: 10.1186/bcr3388.

16.

Endoplasmic reticulum stress induces PRNP prion protein gene expression in breast cancer.

Déry MA, Jodoin J, Ursini-Siegel J, Aleynikova O, Ferrario C, Hassan S, Basik M, LeBlanc AC.

Breast Cancer Res. 2013 Mar 12;15(2):R22. doi: 10.1186/bcr3398.

17.

A complex containing LPP and α-actinin mediates TGFβ-induced migration and invasion of ErbB2-expressing breast cancer cells.

Ngan E, Northey JJ, Brown CM, Ursini-Siegel J, Siegel PM.

J Cell Sci. 2013 May 1;126(Pt 9):1981-91. doi: 10.1242/jcs.118315. Epub 2013 Feb 27.

18.

Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?

Ursini-Siegel J.

Front Oncol. 2013 Feb 13;3:23. doi: 10.3389/fonc.2013.00023. eCollection 2013.

19.

The ShcA SH2 domain engages a 14-3-3/PI3'K signaling complex and promotes breast cancer cell survival.

Ursini-Siegel J, Hardy WR, Zheng Y, Ling C, Zuo D, Zhang C, Podmore L, Pawson T, Muller WJ.

Oncogene. 2012 Nov 29;31(48):5038-44. doi: 10.1038/onc.2012.4. Epub 2012 Jan 30.

PMID:
22286768
20.

Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling.

Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sørlie T, Wärnberg F, Haakensen VD, Helland Å, Naume B, Perou CM, Haussler D, Troyanskaya OG, Børresen-Dale AL.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2802-7. doi: 10.1073/pnas.1108781108. Epub 2011 Sep 9.

21.

Beyond immune surveillance: Stat1 limits tumor growth in a cell-autonomous fashion.

Ursini-Siegel J.

Cell Cycle. 2011 May 1;10(9):1348. Epub 2011 May 1. No abstract available.

PMID:
21464617
22.

Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response.

Ursini-Siegel J, Cory S, Zuo D, Hardy WR, Rexhepaj E, Lam S, Schade B, Jirstrom K, Bjur E, Piccirillo CA, Denardo D, Coussens LM, Brennan DJ, Gallagher WM, Park M, Pawson T, Hallett M, Muller WJ.

Cancer Res. 2010 Oct 15;70(20):7776-87. doi: 10.1158/0008-5472.CAN-10-2229. Epub 2010 Oct 5.

23.

The ShcA adaptor protein is a critical regulator of breast cancer progression.

Ursini-Siegel J, Muller WJ.

Cell Cycle. 2008 Jul 1;7(13):1936-43. Epub 2008 Apr 24. Review.

PMID:
18604176
24.

ShcA signalling is essential for tumour progression in mouse models of human breast cancer.

Ursini-Siegel J, Hardy WR, Zuo D, Lam SH, Sanguin-Gendreau V, Cardiff RD, Pawson T, Muller WJ.

EMBO J. 2008 Mar 19;27(6):910-20. doi: 10.1038/emboj.2008.22. Epub 2008 Feb 14.

25.

Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.

Ursini-Siegel J, Rajput AB, Lu H, Sanguin-Gendreau V, Zuo D, Papavasiliou V, Lavoie C, Turpin J, Cianflone K, Huntsman DG, Muller WJ.

Mol Cell Biol. 2007 Sep;27(18):6361-71. Epub 2007 Jul 16.

26.

Insights from transgenic mouse models of ERBB2-induced breast cancer.

Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ.

Nat Rev Cancer. 2007 May;7(5):389-97. doi: 10.1038/nrc2127. Epub 2007 Apr 19. Review.

PMID:
17446858
27.

TRAIL/Apo-2 ligand induces primary plasma cell apoptosis.

Ursini-Siegel J, Zhang W, Altmeyer A, Hatada EN, Do RK, Yagita H, Chen-Kiang S.

J Immunol. 2002 Nov 15;169(10):5505-13.

28.

CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells.

Tourigny MR, Ursini-Siegel J, Lee H, Toellner KM, Cunningham AF, Franklin DS, Ely S, Chen M, Qin XF, Xiong Y, MacLennan IC, Chen-Kiang S.

Immunity. 2002 Aug;17(2):179-89.

Supplemental Content

Loading ...
Support Center